Project Grant W81XWH1810015

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to conduct preclinical research on antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) develop and evaluate GPR56-targeting ADCs for potent and selective killing of TNBC cells, 2) assess the safety and efficacy of lead GPR56...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will support research to activate the transcription factor EB (TFEB) as a strategy to enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The $400,000 award to Promilead, LLC, with a period of performance from February 1, 2025 to January 31, 2026, will evaluate the toxicity and pharmacokinetics of the TFEB activator compound USCYL01, and test...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel therapy with combined immuno- and onco-targeting capabilities to treat triple negative breast cancer. The $661,072 grant, awarded to Northwestern University on January 1, 2025, will fund research to create a first-in-class small molecule inhibitor targeting the USP22 oncogene, which can inhibit cancer cell growth, impair cancer stem cell properties, and boost...

This Project Grant award, with ID R01CA288851, was provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the University of Wisconsin - Madison. The $619,764 award, spanning January 2025 to December 2029, aims to develop new combination immunotherapy strategies to enhance the anti-tumor efficacy against triple-negative breast cancer (TNBC). The key objectives are to: 1) Increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...

This Project Grant award, with Federal Grant ID R01CA289387, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $657,121 award will fund research at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL to develop a dendritic cell therapy for treating leptomeningeal disease (LMD), a rare and deadly complication of advanced stage breast cancer. The research aims to use polarized conventional type 1 dendritic cells...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $472,447 to Mayo Clinic to conduct preclinical and clinical research on using DNA methyltransferase (DNMT) inhibitors in combination with standard chemoimmunotherapy for treating triple-negative breast cancer (TNBC). The key objectives are to evaluate the activity and mechanisms of action of DNMT inhibitors in DNMT3A-positive TNBC, clinically assess predictive and pharmacodynamic...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $798,512 to Luminary Therapeutics, Inc. to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with current CAR T-cell therapies against solid tumors, including antigen escape and poor T-cell persistence, by using a "split CAR" approach that...

The Leland Stanford Junior University (Stanford University) has been awarded a $462,860 Project Grant from the National Cancer Institute (NCI), an institute of the U.S. Department of Health and Human Services, under the NCI's Cancer Treatment Research program (CFDA 93.395). This 5-year grant supports the development of novel targeted radionuclide therapy (TRT) approaches for the treatment of triple-negative breast cancer (TNBC). The key objectives of this project are to develop MUC1-targeted...